Special Issue "mTOR Signaling: New Insights into Cancer, Cardiovascular Diseases, Diabetes and Aging"
Deadline for manuscript submissions: 31 March 2021.
Interests: cardioprotecton against myocardial ischemia/reperfusion injury with pharmacological agents, including mTOR inhibitor and phosphodiesterase-5 inhibitor; myocardial pre- and post-conditioning; cardioprotective mechanism in diabetic heart; myocardial infarction; cardiac hypertrophy; heart failure; developing a novel pharmacotherapy against doxorubicin-induced or other anti-cancer drug-induced cardiotoxicity; role of nitric oxide, protein kinase G, mTOR signaling, STAT3 signaling, specific long-non-coding RNA, and microRNA in cardioprotection; inflammation; necrosis; apoptosis; autophagy
Special Issues and Collections in MDPI journals
Interests: therapeutic and nutraceutical interventions to prevent or treat cardiovascular, metabolic, and cardiorenal diseases, including atherosclerosis, prediabetes, diabetes, and its microvascular complications (especially nephropathy)
The mechanistic target of rapamycin (mTOR), an atypical multidomain serine/threonine kinase of the phosphoinositide 3-kinase (PI3K) related kinase family, elicits a significant role in integrating intracellular and environmental cues that orchestrate gene transcription, protein synthesis, tissue regeneration and repair, oxidative stress, cell metabolism, growth, proliferation, autophagy, apoptosis, survival, and longevity. Aberrant activation of mTOR is potentially associated with the etiology of many pathological conditions, including cancer, obesity and diabetes, cardiovascular diseases, pulmonary hypertension, and neurodegeneration. Based on its pathophysiological importance, the mTOR signaling pathway has attracted unprecedented attention among basic scientists and clinicians. mTOR is the core component of differently composed signaling complexes, mTORC1 and mTORC2, which phosphorylate distinct specific substrates. It is essential to extensively investigate the differential roles of mTORC1 and mTORC2 signaling pathways in human diseases, which could be targeted selectively or in combination, to develop potential therapeutic or nutraceutical interventions to prevent or treat severe diseases and extend life span.
The editors of this Special Issue welcome original research articles, reviews, meta-analyses/systematic reviews, or shorter perspective articles as well as novel technological approaches with an emphasis on the molecular aspects of mTOR signaling in metabolic syndrome, cardiovascular diseases, cancer, and aging, which would advance our knowledge to develop novel therapeutic or nutraceutical strategies to treat many human diseases.
We look forward to your contributions to this Special Issue.
Dr. Flávio Reis
Dr. Anindita Das
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Apoptosis and autophagy
- Cardiovascular diseases
- Diabetes and other metabolic diseases
- Gene targets and therapeutics
- Growth and proliferation
- mTOR signaling